By staff writers

August 2, 2018 -- Artificial intelligence (AI) software developer Mindshare Medical has received Health Canada clearance for the use of its RevealAI-Lung computer-aided diagnosis (CADx) software in lung cancer screening.

Designed to reduce false positives and shorten the time to diagnosis, the deep learning-based software takes a radiomics approach to assessing lung nodules found on low-dose CT lung screening exams, according to the vendor. RevealAI-Lung generates what the company calls a malignancy similarity index, which is composed of hundreds of CT characteristics that are combined to create a morphological biomarker of malignancy.

The biomarker is then used to compare the nodule being diagnosed with nodules in a reference database that have known diagnostics and outcomes, Mindshare said.

RevealAI-Lung can integrate with a facility's PACS and vendor-neutral archive, the company said.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking